Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics...
Day: June 2, 2025
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical...
LogicMark, Inc. Common Stock to Commence Trading on OTC Markets as the Company Continues Advancing Growth Initiatives
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (the “Company”), a provider of personal emergency response systems (“PERS”), health...
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7...
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed...
Glow Lifetech Reports 238% YoY Revenue Growth and Near-Breakeven EBITDA in Q1 2025, Marking Third Straight Quarter of 40%+ Sequential Revenue Growth
Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or...
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"),...
Silo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War Doctrine
Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo," or the "Company")...
MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits
DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the...
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national...
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),...